Background: There are limited data regarding the clinical outcomes of very long stent implantation, particularly the use of second generation everolimus eluting stents (DES). Methods: From the IRIS-DES Registry, we identified 406 patients who were treated for coronary stenosis using ! 60 mm of overlapping drug-eluting stents. Of these, 269 and 137 patients were treated using cobalt chromium everolimus eluting stent (CoCr-EES) and platinum chromium everolimus-eluting stents (PtCr-EES), respectively. Major adverse cardiac events (MACE) were defined using a composite measure consisting of death, myocardial infarction (MI; periprocedural or spontaneous), or target vessel revascularization (TVR). Results: Per target lesion, the average stent number was 2.7 AE 0.7 and the average stent length was 76.3 AE 14.8 mm. On 2-year clinical follow-up, the rate of MACE, death, spontaneous MI, TVR, and stent thrombosis (definite or probable stent thrombosis) were 31.8%, 4.4%, 2.0%, 7.1%, and 0.5%, respectively. Although 88 patients (21.2%) suffered from periprocedural MI, this was not independently associated with death, spontaneous MI, or TVR (hazard ratio [HR], 1.097; 95% confidence interval [CI] 0.58-2.08, p ¼ 0.775). In addition, there were no statistical differences between CoCr-EES and PtCr-EES implantation in terms of the adjusted risks of MACE (HR, 1.223; 95% CI 0.82-1.82, p ¼ 0.321) as well as its individual components (death; HR, 0.846; 95% CI 0.311-2.305, p ¼ 0.744, MI; HR, 1.101; 95% CI 0.686-1.768, p ¼ 0.690, TVR; HR, 1.854; 95% CI 0.895-3.841, p ¼ 0.097) Conclusions: When treating diffuse coronary stenosis, multiple overlapping stent implantation using second generation DES appear to be safe and effective. Although periprocedural MI frequently occurred, it was not associated with an increase in longterm adverse clinical outcomes.
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Long Term Efficacy and Safety of Ultra-long Everolimus-Eluting Stent Implantation Yohsuke Honda 1 , Ren Kawaguchi 2 , Yusuke Miyaishi 3 , Hakuken Kan 4 , Hiroshi Hoshizaki 5 , Shigeru Oshima 5 , Toshiya Muramatsu 6 1 Saiseikai Yokohama City Eastern Hospital, Yokohama, Kanagawa-ken, 2 Gunma Prefectural Cardiovascular Center, Maebashi, Gunma, 3 Gunma Prefectural Cardiovascular Center, Maebashi, Japan, 4 Gunma prefectural cardiovascular center, Maebashi, Japan, 5 Gunma Prefectural Cardiovascular Center, Maebashi, Japan, 6 Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan Background: Although the long stent implantation was known as a predictor of target lesion revascularization (TLR) or stent thrombosis (ST), EES showed favorable results even in complicated lesions. We aimed to investigate the impact of ultra-long EES(UL-EES) implantation in real-world practices. Methods: A total of 587 consecutive patients(829lesions) who underwent EES implantation were enrolled.According to total stent length,lesions were divided into UL-EES(>50mm,21patients,25lesions),long-EES(L-EES) (30to50mm,69patients,93lesions),short-EES(S-EES) (<30mm,497patients,711lesions).Whole life dual antiplatelet therapy was planned for the Long-EES and UL-EES patients.TLR,definite ST,myocardial infarction (MI),death during follow-up were compared among three groups. Results: Prevalence of coronary risk factors was similar among three groups. Rate of ST-segment elevation MI (STEMI) was higher in L-EES(p¼0.03). Rate of lesiona with chronic total occlusion(p<0.001) and in right coronary artery(p¼0.02) were higher in UL-EES group. Overall death, MACE, MI, TLR and ST was observed in 39patients(6.6%), 61patients(10.3%), 5patients(0.8%), 41lesions(4.9%) and 8lesions(0.9%). In cox proportional-hazards model, stent length>30mm, >50mm, hemodialysis, peripheral artery disease were the independent predictor of TLR (p¼<0.001,0.02,0.03,0.001). STEMI, reference diameter<2.5mm, stent length>30mm were the independent predictor of ST (p¼0.002,0.04,0.003). Rate of TLR and ST was significantly lower in S-EES (3.9%,0.6%) than UL-EES (16%,p¼0.002,4%,p¼0.03) and L-EES (9.7%,p¼0.005,3.2%, p¼0.007) but similar between UL-EES and L-EES (p¼0.42,0.83). Though incidence of MACE was significantly higher in L-EES (19.7%) than in S-EES (16%) (p¼0.02), that was similar between in S-EES and in UL-EES (19%) (p¼0.14). No difference was observed in incidence of death among three groups (p¼0.94). Conclusions: Despite of the use of EES, stent length was related to TLR. However, ultra long EES implantation under prolonged dual antiplatelet therapy showed acceptable TLR rate and safety profile for the patient's hard events.
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Background: In the era of drug-eluting stents, multiple overlapping stents was performed more than 10% of patients with diffuse coronary artery diseases. However, correlation between the location of overlapping site and 9 month follow-up (FU) minimum lumen diameter (MLD) site after multiple overlapping everolimus-eluting stents (EES) was not well evaluated. Methods: From the prospective, multi-center study of XILLION (XIence/promus for Long coronary LesION) registry to assess the efficacy of multiple overlapping EESs in patients with diffuse long coronary artery disease, serial quantitative coronary angiography (QCA) analyses at pre-, post-procedure, and 9month FU were performed for pre-, post-procedural MLD, and overlapping sites. MLD site at FU angiography was independently evaluated by QCA analysis. Results: A total of 330 patients with 348 lesions were enrolled and 9 month FU angiography was performed for all patients. In the 52% of the lesions, the location of pre-procedural MLD was same as that of FU MLD. On the other hand, in the 72 % of the lesions, the location of post-procedural MLD was same as that of FU MLD. All same MLD sites (pre-¼ post-procedure ¼ FU) were observed in 44% of lesions. New MLD site was observed at FU in 8% of lesion. MLD site was observed at overlapping site in 5.3% of the lesion at post-procedure and 1.4% at 9 month FU. No angiographic restenosis was observed at overlapping site. Angiographic data was shown in table. Conclusions: After multiple overlapping stenting, overlapping site was not associated with the location of MLD at pot-procedure and 9 month FU. The location of MLD site at pre-and post-procedure correlated with at 9month FU. 
